Securities Fraud · Consumer Protection · Mass Torts

Seeking accountability for corporate misconduct that harms many people.

Schwartz & Associates, PC represents investors, consumers, and people injured by drugs, medical devices, and products in class actions and mass torts. Every matter starts with research: public records, regulatory filings, market data, and the facts you bring to the firm.

Reviewing your information costs nothing and creates no obligation. What you send is handled under the Privacy Policy. The intake assistant is an AI system, not a lawyer, and gives general information, not legal advice. Please don’t share Social Security or account numbers. How this works · Consumer Health Data Privacy Policy

Cases filed by the firm

Matters in which Schwartz & Associates, PC is counsel of record, not cases filed by other firms.

Firm case

LaChance v. TruGolf Holdings, Inc., et al.

NASDAQ: TRUG · D. Utah · 1:26-cv-00119-JNP-CMR · filed July 24, 2026

The complaint alleges that defendants misrepresented or failed to disclose that holders of TruGolf's Series A Convertible Preferred Stock were continuously converting into Class A shares at floating and ratcheting conversion prices, causing substantial ongoing dilution, and that TruGolf's April 15, 2026 Form 10-K overstated its outstanding Class A shares by 480,504 shares, or approximately 52%. The complaint alleges that the financing and related misstatements contributed to a decline of more than 98% in the split-adjusted price of TruGolf's Class A common stock.

Class period: September 10, 2025 to May 20, 2026
Reported lead plaintiff deadline: September 28, 2026
Claims: Securities Act Sections 11 and 15; Exchange Act Sections 10(b), 14(a) and 20(a); related shareholder derivative claims
The firm's role: Schwartz & Associates, PC is counsel of record for the plaintiff in this action, the first-filed securities class action concerning TruGolf.

Case details Talk to the firm about this case

Public records

Active Securities Class Actions

Upcoming lead plaintiff deadlines in pending securities class actions, compiled from public notices and court dockets as of September 11, 2026.

All Active Cases

Company	Class period	Reported lead plaintiff deadline	Details
Planet Fitness, Inc. NYSE: PLNT	November 6, 2025 to May 6, 2026	September 14, 2026	Details
Regeneron Pharmaceuticals, Inc. NASDAQ: REGN	August 1, 2025 to May 15, 2026	September 14, 2026	Details
GPGI, Inc. NYSE: GPGI	November 3, 2025 to May 6, 2026	September 14, 2026 or September 15, 2026	Details
Cogent Communications Holdings, Inc. NASDAQ: CCOI	February 29, 2024 to May 1, 2026	September 21, 2026	Details
EquipmentShare.com Inc. NASDAQ: EQPT	January 23, 2026 to June 23, 2026	September 21, 2026	Details
Microvast Holdings, Inc. NASDAQ: MVST	April 1, 2025 to March 16, 2026	September 21, 2026	Details

A lead plaintiff deadline applies only to an investor who wants to ask the court to lead the case. Class members do not need to act by that date to remain in the class, but they ordinarily must submit a claim form to be paid and are bound by the result unless they opt out. Unless marked Firm case, the firm is not counsel in these cases. How lead plaintiff deadlines work

Mass Tort Litigation

Drug, medical device, product, and exposure litigation in which new claims are being filed, with the federal MDL where each is coordinated.

All Mass Torts

MDL 3140

Depo-Provera (meningioma)

Plaintiffs allege the injection caused intracranial meningioma and that Pfizer failed to warn of that risk.

Depo-Provera remains approved by the U.S. Food and Drug Administration.

Ask about this

MDL 3094

GLP-1 drugs: Ozempic, Wegovy, Mounjaro and others (gastroparesis and GI injuries)

Plaintiffs allege gastroparesis and related gastrointestinal injuries and inadequate warnings.

Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro remain approved by the U.S. Food and Drug Administration.

Ask about this

MDL 3060

Chemical hair relaxers and straighteners (uterine and other cancers)

Plaintiffs allege that chemical hair relaxers caused uterine, breast and other cancers.

Ask about this

MDL 2873

AFFF firefighting foam / PFAS exposure (cancers and other diseases)

Plaintiffs allege PFAS exposure from AFFF caused diseases including kidney cancer, testicular cancer, ulcerative colitis, thyroid disease, liver cancer and thyroid cancer.

Ask about this

MDL 3081

Bard implanted port catheters (PowerPort)

Plaintiffs allege device failures including catheter fracture and infection, asserting design defect and failure to warn.

Bard implanted port products remain cleared by the U.S. Food and Drug Administration for sale. Certain product lots have been recalled; the FDA recall database lists specific products.

Ask about this

MDL 3029

Covidien (Medtronic) hernia mesh

Plaintiffs allege complications from Covidien hernia mesh and that the company failed to adequately warn of mesh risks.

Certain Covidien hernia mesh products have been recalled, including a 2023 recall of a Parietex composite mesh product; other Covidien mesh products remain cleared by the U.S. Food and Drug Administration for sale.

Ask about this

Schwartz & Associates, PC is responsible for the content of this website. Responsible attorney: Lou Schwartz, Esq. The firm may refer matters to, or handle them together with, other lawyers. Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Consult your physician before making any decision regarding prescribed medication or medical treatment.

Practice Areas

Class and mass actions arising from conduct that harms many people in the same way, and a corporate practice built on the same judgment.

Securities Fraud & Shareholder Litigation

Securities class actions, shareholder derivative suits, merger litigation, and opt-out actions for investors harmed by false or misleading disclosures.

Securities practice

Consumer Protection & Data Privacy

Class actions over deceptive practices, hidden fees, automatic renewals, data breaches, and tracking or disclosure of personal information without consent.

Consumer practice

Mass Torts

Injury claims involving prescription drugs, medical devices, consumer products, and environmental exposure, including cases coordinated in federal MDLs.

Mass tort practice

Corporate & Advisory

Counsel for founders, executives, boards, and investors on transactions, governance, and decisions that will be scrutinized later.

Corporate practice

Litigation informed by how companies actually operate.

The firm's founder built his career as a corporate securities and M&A lawyer and as a chief executive and board chair of public and private companies. That experience shapes how the firm reads disclosures, incentives, and internal controls, and how it evaluates what a company knew and when it knew it.

About the Firm

Our Method

Research-driven litigation

Matters are identified through public records, regulatory filings, market data, and consumer complaints, then tested against the law and the evidence before anything is filed.

01.

Issue identification

Recurring conduct, found in the record before it becomes a headline.

02.

Legal evaluation

Whether the conduct supports cognizable claims, and whether the proof will be admissible.

03.

Litigation

Claims prosecuted, by the firm alone or with co-counsel, where the evidence supports them.

Our Method

Insights

Recent developments in securities, mass tort, consumer protection, and corporate law, summarized for the people they affect.

All Insights

Securities & ShareholderSeptember 9, 2026Firm case: securities class action filed over TruGolf share dilutionThe reported lead plaintiff deadline is September 28, 2026, and it applies only to an investor who wants to ask the court to lead the case; class members do not need to act by that date to remain in the class.Mass TortsSeptember 4, 2026Jury awards $40 million in Bard implanted port bellwether trialBellwether verdicts inform, but do not decide, the roughly 3,700 other cases pending in the MDL, and post-trial motions or an appeal may follow.Consumer & Data PrivacyAugust 28, 2026California Legislature passes SB 690 limiting certain CIPA lawsuitsIf signed, the bill would bar private suits under section 638.51 over website and app tracking, including pending claims in suits filed on or after January 1, 2025, while claims under sections 631 and 632 would remain available.

Common questions

Do I need to do anything to be part of a class action?

Generally, no. If a court certifies a class, people who meet the class definition are ordinarily included without taking any action. To receive money from a settlement, however, class members usually must submit a claim form by a deadline, and a class member who does not opt out by the deadline in the court's notice is bound by the result.

What does it cost to have my matter reviewed?

Reviewing your information costs nothing and creates no obligation. If the firm takes a matter, the fee arrangement is set out in a written agreement. In a class action, attorneys' fees are paid from any recovery and are subject to court approval.

How is a mass tort different from a class action?

In a mass tort, each injured person has their own case and their own damages, even when the cases are coordinated before one judge. In a class action, representatives sue on behalf of a group, and the result binds class members who do not opt out.

If something happened to more people than you, tell us.

Many class actions begin with one person who noticed a pattern. Reviewing your information costs nothing and creates no obligation.

Case Evaluation or call (918) 238-6445

Corporate & Advisory

The firm also advises founders, executives, boards, and investors on financings, acquisitions, governance, and decisions that will be scrutinized later.

Corporate Practice